Cancer Family

Lymphocytic Neoplasm

HematologicNon-malignant3,037 active trials72 approved drugs345 evidence items

NCIt: C7065

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Literature

Linked publications (347)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedPublishedShowing 1–25 of 347 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Serologic follow-up in patients with multiple myeloma without repeated bone marrow studies: a single-institution experience.
Lidia Joanna Alberto-López, Oscar Emigdio Melchor-Melo, Miguel Ángel Gómez-Cabrera et al. · Hematology · Dec 31, 2026 · PMID 42685232 · candidate dictionary pubmed
Clinical features and management of GPRC5D-associated adverse events in novel GPRC5D × CD3 bispecific talquetamab-treated relapsed/refractory multiple myeloma patients: the MonumenTAL-1 China cohort experience.
Gang An, Jie Jin, Zhen Cai et al. · Hematology · Dec 31, 2026 · PMID 42679119 · candidate dictionary pubmed
STAT3 inhibition for the induction of immunogenic cell death in multiple myeloma.
Oliver Kepp, Guido Kroemer · Oncoimmunology · Dec 31, 2026 · PMID 42740603 · candidate dictionary pubmed
miR-877-5P acts as a tumor suppressor in multiple myeloma by targeting MAPK8: a study on prognostic value and functional mechanism.
Zhimin Bai, Qiulian Luo, Shasha Zhao · Hematology · Dec 31, 2026 · PMID 42781717 · candidate dictionary pubmed
Development and internal validation of a machine learning model for predicting second primary malignancy risk in hodgkin lymphoma survivors: a population-based competing risk analysis.
Sinian Li, Mingyue Xiong, Zhonggui Gan et al. · Hematology · Dec 31, 2026 · PMID 42804656 · candidate dictionary pubmed
Global trends in CAR-T cell therapy for multiple myeloma: A bibliometric analysis, 2013-2025.
Tiantian Zhang, Shenyu Wang, Xin Li et al. · Hum Vaccin Immunother · Dec 1, 2026 · PMID 42623170 · candidate dictionary

pubmed

Cost-effectiveness analysis of elranatamab versus physician's choice of treatment (non-BCMA-directed regimens) in patients with triple class exposed multiple myeloma in Japan.

Akira Yuasa, Mitsuhiro Nagano, Yoichi Kamei et al. · J Med Econ · Dec 1, 2026 · PMID 42709039 · candidate dictionary pubmed

Patient-derived mesenchymal stromal cells establish an IL-6 axis that marks progression from smouldering to active multiple myeloma.

Phoebe Elizabeth Blair, Tianyuan Chu, Andrew Robinson et al. · Cytokine · Nov 1, 2026 · PMID 42721887 · candidate dictionary pubmed

CD200 is a potent new growth factor in Multiple Myeloma dependent on IGF1 receptor signaling.

Angélique Bruyer, Nicolas Robert, Jules Varbedian et al. · Transl Oncol · Oct 1, 2026 · PMID 42664786 · candidate dictionary pubmed

Single-cell and bulk transcriptomic profiling of M2-like tumor-associated macrophages reveals a prognostic signature and an inflammation-metabolism crosstalk program in multiple myeloma.

Hui Zhao, Jing Kang, Huiling Ouyang et al. · Transl Oncol · Oct 1, 2026 · PMID 42636658 · candidate dictionary pubmed

NSD2 degradation remediates the oncogenic cistrome in t(4;14) multiple myeloma.

Bo Hu, Jacob T Edwards, Hardik Modi et al. · Blood · Sep 24, 2026 · PMID 42371798 · candidate dictionary pubmed

Validation of the newly introduced Deauville score 5a for patients treated for advanced-stage classic Hodgkin lymphoma.

Simon Leiders, Dominic Ufton, Helen Kaul et al. · Blood Adv · Sep 22, 2026 · PMID 42379221 · candidate dictionary pubmed

Evolution of real-world frontline treatment patterns in multiple myeloma.

Alexander Lazzaro, Kaelyn Nannini, Cenk Yildirim et al. · Blood Adv · Sep 22, 2026 · PMID 42480210 · candidate dictionary pubmed

AI-derived whole-body MRI metrics in patients with multiple myeloma reveal unique insights into body composition and outcomes.

Nicolas Basty, Martin Kaiser, Charlotte Pawlyn et al. · Blood Adv · Sep 22, 2026 · PMID 42418394 · candidate dictionary pubmed

Exploring the psychological impact and healthcare experiences of patients living with triple class refractory multiple myeloma: an interpretative phenomenological analysis study.

Noreen Ali, Luke Kuttschreuter, Sandra Quinn et al. · BMJ Open · Sep 21, 2026 · PMID 42767746 · candidate dictionary pubmed

Mosunetuzumab With Response-Adapted Polatuzumab Vedotin and Obinutuzumab in Untreated Indolent B-Cell Non-Hodgkin Lymphoma.

Ryan C Lynch, Christina Poh, Mazyar Shadman et al. · J Clin Oncol · Sep 20, 2026 · PMID 42600120 · candidate dictionary pubmed

Psychometric evaluation of the PROMIS® Medication Adherence Scale among patients prescribed oral anticancer medication for multiple myeloma.

Sarah M Belcher, Paul Scott, Susan M Sereika et al. · J Patient Rep Outcomes · Sep 19, 2026 · PMID 42791413 · candidate dictionary pubmed

SEI1 complex silences p53 to drive myeloma progression.

Rui Chen, Rui Liu, Zhihong Fang et al. · iScience · Sep 18, 2026 · PMID 42698665 · candidate dictionary pubmed

Two decades of progress, persistent inequity: national trends in multiple myeloma mortality in the United States, 1999-2024.

Mohammad Eisa Ali, Federico Ferrari, Ali Shan Hafeez et al. · Cancer Causes Control · Sep 18, 2026 · PMID 42754761 · candidate dictionary pubmed

PKMYT1 is a targetable vulnerability in del(17p) high-risk multiple myeloma.

Anaïs Schavgoulidze, Jian Cui, Jessica Encinas Mayoral et al. · Blood · Sep 17, 2026 · PMID 42237635 · candidate dictionary pubmed

Belantamab mafodotin plus venetoclax in t(11;14)-positive relapsed or refractory multiple myeloma - the BELI(E)VE trial.

Christoph Schaefers, Cyrus Khandanpour, Mathias Hänel et al. · BMC Cancer · Sep 16, 2026 · PMID 42786443 · candidate dictionary pubmed

The NSDHL/c-Myc/PKM2 Axis Drives Glycolytic Reprogramming and Tumor Growth in Multiple Myeloma.

Can Yue, Bei-Hui Huang, Lin Qi et al. · Int J Mol Sci · Sep 16, 2026 · PMID 42794667 · candidate dictionary pubmed

Innate immune dysregulation in multiple myeloma: molecular basis and mechanistic interventions.

Gang Wang, Hanlin Gao, Tianyi Xie et al. · Int Immunopharmacol · Sep 15, 2026 · PMID 42314557 · candidate dictionary pubmed

Imaging B cell maturation antigen in multiple myeloma.

Yangmeihui Song, Wenyu Song, Weibo Cai · J Clin Invest · Sep 15, 2026 · PMID 42741935 · candidate dictionary pubmed

A single-arm prospective phase I trial of 68Ga-PFBC01 PET/CT for multiple myeloma B cell maturation antigen imaging.

Tingfei Gu, Zhao Chen, Bo Tang et al. · J Clin Invest · Sep 15, 2026 · PMID 42378054 · candidate dictionary pubmed